New Capital to Support Continued Advancement of Novel Technology and
LA JOLLA, Calif., Nov. 8 /PRNewswire/ -- Anaptys Biosciences, Inc., a privately-held therapeutic antibody product company, today announced that it has raised $33.9 million in a Series B equity financing led by Novo A/S. Additional investors participating significantly in the round were Frazier Healthcare Ventures and Alloy Ventures, along with founding investor Avalon Ventures. Completing the syndicate were Numenor Ventures, WS Investment Company, and Anaptys board member, Dr. Nick Lydon.
The new investment capital will support continued advancement of the company's novel technology for therapeutic antibody discovery and optimization, and building a pipeline of product candidates.
"We are pleased to have attracted such a strong investor group to support the company's multiple development programs," said Tom Smart, chairman and chief executive officer of Anaptys. "In addition to providing significant financial resources, these experienced investors bring Anaptys a wealth of operational, medical, and industry expertise along with key relationships that will serve the company well during this important stage of growth and achievement."
In connection with the financing, Heath Lukatch, Ph.D., of Novo A/S, James N. Topper, M.D., Ph.D., of Frazier Healthcare Ventures, and J. Leighton Read, M.D., of Alloy Ventures will join the Anaptys Board of Directors together with existing members Kevin J Kinsella of Avalon Ventures, Nick Lydon, Ph.D., of Granite Biopharma, LLC, R. Scott Greer of Numenor Ventures, and Anaptys executives William Boyle, Ph.D., and Tom Smart.
"It is a great pleasure for Novo A/S to lead this investment in
Anaptys," said Dr. Lukatch. "The company has developed powerful
technologies to quickly and cost effectively optimize antibodies against a
variety of high value targets. By harnessing the efficiency of
|SOURCE Anaptys Biosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved